Niraparix is named as an intervention in 2 current clinical trials in our China and Poland registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1). The most-studied condition is Rare Tumor.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
PLATFORM Study of Precision Medicine for Rare Tumors
NCT04423185 · ClinicalTrials.gov ↗ · Rare Tumor
|
Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | China |
|
Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.
NCT06614790 · ClinicalTrials.gov ↗ · Ovarian Cancer
|
Observational | Recruiting | Pomeranian Medical University Szczecin | Poland |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Pomeranian Medical University Szczecin | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Poland | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Poland registers name Niraparix (also registered as Niraparib 200) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in China and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) and Pomeranian Medical University Szczecin (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Niraparix works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Niraparix works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Niraparix (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.